Kite, a Gilead Company, and Shoreline Biosciences have announced a $2.3 Billion strategic partnership to develop novel cell therapies across a variety of cancer targets.
Shoreline to receive payments totaling over $2.3 billion
Shoreline Biosciences, a U.S. biotechnology company developing intelligently designed allogeneic off-the-shelf, standardized and targeted natural killer (NK) and Macrophage cellular immunotherapies derived from induced pluripotent stem cells (iPSC) for cancer and other serious diseases will receive an upfront payment and will be eligible to receive additional payments totaling over $2.3 billion as well as royalties based on reaching certain development and commercial milestones, under the terms of the agreement.
The partnership will leverage Shoreline’s rich expertise in iPSC differentiation and genetic reprogramming in combination with Kite’s broad cell therapy development, commercialization and manufacturing expertise to develop novel allogeneic candidates for a range of hematologic malignancies. The collaboration will focus initially on chimeric antigen receptor (CAR) NK targets, with Kite having an option to expand the collaboration to include an iPSC CAR Macrophage program for an undisclosed target to be selected post-deal execution. This agreement follows Kite’s investment in Shoreline’s recent Series A financing.
Mert Aktar, Vice President of Corporate Development and Strategy at Kite stated:
“As the leader in cell therapy, we are focused on investing in and delivering on the most promising opportunities to further optimize the therapeutic potential of cell therapy. We are excited about the potential of Shoreline’s next-generation approach to allogeneic development, and how our collaboration can accelerate this research across different leukemias and lymphomas.”
Kleanthis G. Xanthopoulos, Ph.D., Shoreline Co-Founder, Chairman and CEO sated:
“We’re thrilled to strengthen our relationship with Kite, which has been at the forefront of cancer immunotherapy for over a decade, through this strategic partnership. The combined strength of Kite’s leadership in CAR T-cell therapies and our cutting-edge iPSC platform will potentially accelerate Shoreline’s timeline to the clinic, expand our pipeline opportunities and deliver transformational treatment options for cancer.”
About Shoreline Biosciences
Shoreline is a biotechnology company dedicated to furthering the development of intelligently designed allogeneic off-the-shelf, targeted and standardized cellular immunotherapies for cancer and other serious diseases. Shoreline is building a pipeline of natural killer (NK) cell and macrophage-cell therapy candidates derived from its deep expertise in iPSC differentiation methods and genetic reprogramming of disease-relevant pathways. Shoreline has a strategic manufacturing relationship with the Advanced Cell Therapy Laboratory and is supported by high-quality institutional investors including Boxer Capital, BVF Partners L.P., Commodore Capital, Cormorant Capital, Janus Henderson Investors, Logos Capital, Kite, a Gilead Company, Wedbush Healthcare Partners, Stork Capital and others. Shoreline Biosciences is headquartered in San Diego, CA. For more information, please visit https://shorelinebio.com/
Kite, a Gilead Company, is a global biopharmaceutical company based in Santa Monica, California, with commercial manufacturing operations in North America and Europe. Kite’s singular focus is cell therapy to treat and potentially cure cancer. As the cell therapy leader, Kite has more approved CAR T indications to help more patients than any other company. For more information on Kite, please visit www.kitepharma.com.